Margiotta, Nicola, Marzano, Cristina, Gandin, Valentina, Osella, Domenico, Ravera, Mauro, Gabano, Elisabetta, Platts, James Alexis ORCID: https://orcid.org/0000-0002-1008-6595, Petruzzella, Emanuele, Hoeschele, James D. and Natile, Giovanni 2012. Revisiting [PtCl2(cis-1,4-DACH)]: an underestimated antitumor drug with potential application to the treatment of oxaliplatin-refractory colorectal cancer. Journal of Medicinal Chemistry 55 (16) , pp. 7182-7192. 10.1021/jm3006838 |
Abstract
Although the encouraging antitumor activity of [PtCl2(cis-1,4-DACH)] (1; DACH = diaminocyclohexane) was shown in early studies almost 20 years ago, the compound has remained nearly neglected. In contrast, oxaliplatin, containing isomeric 1R,2R-DACH carrier ligand, enjoys worldwide clinic application as a most important therapeutic agent in the treatment of colorectal cancer. By extending the investigation to human chemo-resistant cancer cells, we have demonstrated the real effectiveness of 1 in circumventing cisplatin and oxaliplatin resistance in LoVo colon cancer cells. The uptake of compound 1 by the latter cells was similar to that of sensitive LoVo cells. This is not the case for all other compounds considered in this investigation. Interaction with ds-DNA, investigated by a biosensor assay and by QM/MM geometry optimization of the 1,2-GG intrastrand cross-link, does not show significant differences between 1 and oxaliplatin. However, the DNA adducts of 1 are removed from repair systems with lower efficiency and are more effective in inhibiting DNA and RNA polymerase.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Advanced Research Computing @ Cardiff (ARCCA) Chemistry |
Subjects: | Q Science > QD Chemistry |
Publisher: | American Chemical Society |
ISSN: | 0022-2623 |
Last Modified: | 21 Oct 2022 08:57 |
URI: | https://orca.cardiff.ac.uk/id/eprint/34873 |
Citation Data
Cited 65 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |